Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
| Autor: | Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young, Allan Wailoo |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Health Technology Assessment, Vol 20, Iss 35 (2016) |
| Druh dokumentu: | article |
| ISSN: | 1366-5278 2046-4924 |
| DOI: | 10.3310/hta20350-c201611 |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|